Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets by unknown
SURFACE  ANTIGENS  OF  MELANOCYTES  AND  MELANOMAS 
Markers  of Melanocyte  Differentiation  and  Melanoma  Subsets* 
By ALAN  N.  HOUGHTON,:,  MAGDALENA  EISINGER, ANTHONY  P.  ALBINO, 
J.  GREGORY  GAIRNCROSS,:~ AND LLOYD J.  OLD 
From the Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New  York, New  York 10021 
Knowledge about  the surface antigens of malignant melanoma has grown rapidly 
since the advent of monoclonal antibodies (1-5). A  large number of cell lines derived 
from melanomas have now been established, and these have facilitated the serological 
analysis of melanoma  surface antigens.  Many  of the  melanoma  antigens  that  have 
been identified with mouse monoclonal antibodies are not expressed by all melanoma 
lines  but  show  instead  a  differential  pattern  of expression  that  defines  melanoma 
subsets on the basis of surface antigenic phenotype. It seems likely that this diversity 
of melanoma phenotype reflects a corresponding diversity in the surface phenotype of 
normal cells undergoing melanocyte differentiation. To pursue this idea, we analyzed 
the surface antigens of melanocytes, using a  recently described method  for growing 
melanocytes from normal skin (6). Most, but not all, of the antigens initially detected 
on  melanomas  were  also  detected  on  melanocytes,  and  the  pattern  of  antigen 
expression  on  newborn  and  adult  melanocytes could  be  distinguished.  From  these 
studies  of melanocytes  and  melanomas,  we  propose  a  scheme  of surface  antigenic 
changes occurring during melanocyte differentiation and a classification of melanoma 
based on expression of melanocyte differentiation antigens. 
Materials  and  Methods 
Melanocyte Cultures.  Skin from face, trunk, or thigh of 16 adults, foreskin of 14 newborns, 
and  skin  from  the  trunk of a  12-wk  fetus served  as the source of melanocytes. Cultures of 
melanocytes were grown in the presence of the phorbol ester, TPA (12-O-tetradecanoyl-phorbol- 
13-acetate)  10 ng/ml  (Consolidated Midland Corp., Brewster, NY), and  1 ×  10 -s M  cholera 
toxin (Schwartz/Mann Div., Becton, Dickinson & Co., Orangeburg, NY), according to previ- 
ously published procedures (6). 
Melanoma Cultures.  For derivation of melanoma cell lines, see ref 7. Cultures were maintained 
in Eagle's minimum essential medium supplemented with either 10% fetal bovine serum (FBS) 
or 8% newborn calf serum mixed with 2% FBS, 2 mM glutamine, 1% nonessential amino acids, 
100  U/ml penicillin, and  100 #g/ml streptomycin. Cultures were regularly tested for myco- 
plasma,  and  contaminated  cultures  were  discarded.  Five melanoma  cell  lines  were  tested 
between passage one and three (SK-MEL-65,163,164,165,173),  while the remaining cell lines 
were tested after passage 8, usually between passages 15 and 50. In addition, eight melanoma 
cell lines (SK-MEL-13,19,28,37,64,127,130,  and MeWo) were grown in the presence of TPA 
(10 ng/ml) and cholera toxin (1  X  10  -s M) for 2-3 wk to determine the effect of these growth 
factors on surface antigen expression. 
Serological Procedures.  The anti-mouse immunoglobulin (anti-Ig) assay and protein A  (PA) 
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assays were performed as described previously (3,  8).  Indicator cells were prepared by conju- 
gating purified anti-mouse immunoglobulin (Dako Corp., Santa Barbara,  CA)  or protein A 
(Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N  J)  to human erythrocytes 
using 0.01%  chromium chloride. Assays were performed in  Falcon  3040  Microtest II  plates 
(Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard, CA).  Sera were incubated with 
target cells for 1 h  at 20°C. Target cells were then washed, and indicator cells were added for 
1 h. Plates were washed and evaluated for rosetting by light microscopy. Titers corresponded 
to  the serum  dilution giving 50%  positive target  cells. Absorption tests were carried out  as 
described (3,  7, 8). 
Serological Reagents (See  Table I).  Monoclonal antibodies were derived from spleen cells of 
mice immunized with melanoma, glioma, renal cancer, or melanocyte cell cultures (3, 9,  I0; A. 
Houghton and A. Albino, unpublished results), nu/nu mice (Swiss background) were inoculated 
with cloned hybridomas, and sera from tumor-bearing mice were used for serological analysis. 
TABLE  I 
Panel of Mouse Monoclonal Antibodies Detecting Cell Surface Antigens of Melanomas and Melanocytes 
Cell surface 
antigen  Original designation of 
monoclonal antibody  Immunizing cell type  Reference 
system 
M-1  L1-27 
M-2  A010 
M-3  A092 
M-4  MIll 
M-5  M231 
M-6  A  J8 
M-7  AJ17 
M-8  D14 
M-9  Mel- 1  * 
M-10  M144 
M-11  A1-27 
M-12  L166 
M-13  E20 
M-14  AJ225 
M-15  AJ9 
M-16  KIll4 
M- 17  A  J60 
M-18  R24 
M-19  I~2, L10, Ks, L235 
M-20  LI01, Q.a4, 0_04, 829, 846 
M-21  I~4 
M-22  R8 
M-23  L2-30, L254 
M-24  M 138 
M-25  M3-68 
M-26  A 123 
M-27  A124 
M-28  B5 
M-29  A  J2 
M-30  A  J10 
M-31  A050 
M-32  A0122 
M-33  V2 
M-34  $6 
Melanoma SK-MEL-33 
Glioma SK-AO-2  10 
Glioma SK-AO-2  10 
Cutaneous melanncytes 
Cutaneous melanocytes 
Glioma AJ  10 
Glioma AJ  10 
Melanoma DX-2 
12 
Cutaneous melanocytes 
Melanoma SK-MEL-  19 
Melanoma SK-MEL-33 
Melanoma SK-MEL-93 
Glioma AJ  10 
Glioma AJ  10 
Melanoma SK-MEL-31 
Glioma AJ  10 
Melanoma SK-MEL-28  3 
Melanoma SK-Mel-28,33  3 
Melanoma SK-MEL-28,33,93  3 
Melanoma SK-MEL-28  3 
Melanoma SK-MEL-28  3 
Melanoma SK-MEL 33 
Cutaneous melanocytes 
Cutaneous melanocytes 
Melanoma SK-MEL-  19 
Melanoma SK-MEL-19 
Melanoma SK-MEL~93 
Glioma AJ 
Glioma AJ 
Glioma SK-AO-2 
Glioma SK-AO-2 
Renal cancer SK-RC-6 
Renal cancer SK-RC-7 
10 
10 
10 
10 
9 
9 
* Defined by naturally occurring antibody in human serum that detects the Mel- 1 melanocyte differentation 
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These sera had maximum titers of ~-~10  -4, and usually >10  -5, with melanoma or melanocyte 
cultures. With the exception of M-18 antibody, which was detected by PA assays, all other 
mouse monoclonal antibodies were analyzed using the anti-Ig assay. Monoclonal antibodies 
known to identify the same epitope or different epitopes on the same molecule were grouped 
under the same antigenic system; M-19 antigen is a 95-kd glycoprotein detected by four mouse 
monoclonal antibodies, M-20 represents a  130-kd glycoprotein detected by five different mouse 
monoclonal antibodies, and M-23 is a glycoprotein dimer of 145 kd and 100 kd detected by two 
antibodies. Mouse monoclonal antibody and conventional rabbit antisera to/32-microglobulin 
(018b) were purchased from Accurate Chemical and Scientific Corp., Westbury, NY. Serological 
and biochemical characteristics of the human HLA-DR monoclonal antibody 13-17 have been 
published (1, 11). Antigen M-9 was detected by a naturally occurring antibody in the serum of 
a healthy individual; this antibody defines a melanocyte differentiation antigen, Mel-1, which 
is expressed by ~50% of melanoma cell lines (12). 
Tyrosinase Assay.  Tyrosinase  activity  was  measured  using  a  modification  of  the  assay 
described by Pomerantz  (13).  [3H]Tyrosine (specific activity, 53.1  Ci/mMol) was purchased 
from New England Nuclear (Boston, MA). Cell lines to be tested were seeded at a density of 1 
X  10  6 cells per flask in 25 cm  2 Falcon flasks. After 12 h, medium was removed and replaced 
with 4 ml fresh medium containing 5 pCi [3H]tyrosine, and the cultures were incubated for an 
additional 24 h. Residual [3H]tyrosine in the medium was removed by adsorption to activated 
charcoal and  passage over a  Dowex  50w  column  (Bio-Rad  Laboratories, Richmond,  CA). 
Tritiated H20 (generated by tyrosinase activity) in the eluent was counted in triplicate in a LS 
9000 Beckman Scintillation Counter (Beckman Instruments, Inc., Fullerton, CA). Tyrosinase 
activity was  expressed as  the  ratio of tritiated H20  generated  by melanoma  cell lines per 
tritiated H20 generated by a control nonpigmented renal cancer cell line (SK-RC-7). 
Results 
Description of Antibodies Reactive with Cell Surface Antigens  of Melanoma and Melanocytes. 
The panel of typing antibodies used in this study is described in Table I, and reactivity 
and  titer of these antibodies with  melanoma cell lines are shown  in Table II. Fig.  1 
illustrates  individual  assays  with  antibodies  detecting  M-4,  M-10,  and  HLA-DR 
antigens tested on three melanoma cell lines and two melanocyte cultures. 
A  characteristic of the  typing antibodies listed  in  Table  I  is  that  they  generally 
react  with only a  proportion of the melanoma cell lines and  therefore divide mela- 
nomas  into  distinguishable subsets  on  the  basis  of antigenic  phenotypes.  Antigens 
such as M-25 are expressed by most melanoma lines (23/26 lines), antigens M-4 and 
M-9  are detected on  approximately one-half of the cell lines, and  M-10  antigen  is 
found  on  only  5  of 33  melanoma  lines.  With  regard  to  major  histocompatibility 
complex  (MHC)  products,  HLA-DR  expression  was  found  on  13  of 21  cell  lines. 
Antibodies to HLA-A,B,C and/~2-microglobulin were highly reactive with nearly all 
melanoma cell lines; two lines, SK-MEL-19 and SK-MEL-33, showed no reaction. By 
absorption tests, these antigens were detectable on SK-MEL-19 but not on SK-MEL- 
33. 
Serological Typing of Fetal, Newborn, and Adult Melanocytes.  Fig. 2 shows the morphol- 
ogy of melanocytes from  newborn  and  adult skin.  Fetal and  newborn  melanocytes 
grow as bipolar cells. In contrast, melanocytes from adult skin show a  polydendritic 
morphology. Fig. 3 summarizes the results of serological tests with newborn and adult 
melanocytes.  The  reactivity of melanocytes  derived  from  fetal  skin  was  similar to 
newborn melanocytes. 
Melanocyte antigens detected  by the panel  of typing antibodies can  be  grouped 
into four categories: (a) not detected on newborn or adult melanocytes but expressed 
by subsets of melanoma:  HLA-DR,  M-l,  M-2,  and  M-3;  (b)  detected on  newborn 
melanocytes but not adult melanocytes: M-4 to M-8; (c) detected on adult melanocytes 1758  SURFACE ANTIGENS OF  MELANOCYTES  AND  MELANOMAS 
TABLE  II 
Serological Typing of Melanoma Cell Lines by Mouse Monoclonal Antibodies 
Cell surface antigen  Melanoma cell lines 
system  reactive/tested (titer range) 
HLA-A,B,C  9/11  (10  -5  10  -6) 
fl2-microglobulin  37/38* 
ttLA-DR  13/21  (10 a-10-5) 
M-1  5/32  (10  -4  10 s) 
M-2  6/28  (10  -a  10  -5  ) 
M-3  17/31  (10 a-10  4) 
M-4  16/33  (10-4-10 -7) 
M-5  10/23  (10  -a  10 5) 
M-6  12/31  (10 a-10  5) 
M-7  10/10  (10 4-10-5) 
M-8  17/18  (10 4-10-5) 
M-9  22/43  (10  -2  10  -5) 
M-10  5/33  (10-a-10 -4) 
M-I1  19/33  (10  -4  10 6) 
M-12  16/19  (10 4-10-6) 
M-13  15/15  (10-5-10 -6) 
M-14  3/13  (10  -a  10 ~) 
M-15  10/10  (10 4-10  5) 
M-16  10/34  (10  -a  10  -~) 
M-17  16/16  (10  -3  10 '~) 
M-18  16/16  (10 3-10-5) 
M-19  20/29  (10-4-10 -6) 
M-20  24/27  (10-5-10 -6) 
M-21  16/16  (10-a-10  5) 
M-22  9/16  (10-4-10  6) 
M-23  19/19  (10 5-10-7) 
M-24  22/26  (10 5-10-7) 
M-25  23/26  (10-5-10 -6) 
M-26  17/19  (10 4-10  7) 
M-27  /4/33  (10 3-10-6) 
M-28  9/10  (10-4-10 -5) 
M-29  10/10  (10-5-10 -6) 
M-30  9/10  (10 s-10-6) 
M-31  8/10  (10-4-10 -6) 
M-32  8/10  (10-4_10 6) 
M-33  6/6  (10 5-10  6) 
M-34  2/30  (10 3-10 4) 
* Determined by absorption tests; rabbit antihuman flz-microglobulin (diluted 
according  to endpoint) was absorbed  with individual melanoma cell lines 
and residual  antibody activity tested  against a standard melanoma target 
cell line (SK-MEL-28). 
and only weakly or not at all on most newborn melanocytes: M-9 and M-10; and (d) 
detected equally on both newborn and adult melanocytes: M- 11 to M-34. Most of the 
antigens in this last group were also expressed by the majority of melanoma cell lines. 
M-34  antigen  was  an  exception  in  this  regard,  as  it  was  detected  on  only  2/30 
melanoma cell lines, as compared  with  14/14  fetal, newborn, and adult  melanocyte 
cultures. The monoclonal antibody recognizing M-34 detects  a  120,000 Mr glycopro- 
tein  that  is  expressed  by  renal  cancer,  normal  kidney  epithelium,  and  a  limited 
number of nonrenal cells (9). HOUGHTON,  EISINGER,  ALBINO,  CAIRNCROSS,  AND  OLD  1759 
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FIC.  1.  Serological  typing of melanocytes and melanoma cells  for HLA-DR, M-4, and M-10 cell 
surface antigens.  Anti-Ig assay. 
Fla.  2.  Morphology  of melanocytes  from  newborn  foreskin  (A)  and  adult  skin  (B).  Newborn 
melanocytes have a bipolar morphology, whereas adult melanocytes are polydendritic. Magnifica- 
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Fro.  3.  Serological  typing of newborn and adult melanocytes  for melanoma cell surface antigens. 
Each circle represents  an individual test, and each test for a particular antigen was performed with 
melanocytes  from  a  different individual.  In the case of tests  with  mouse  monoclonal antibodies, 
black circles represent  antibody  titers  1:10  4  to  1:10 7,  stippled  circles  1:500 to  1:5,000, and  open 
circles _<1:250. In tests  with human  typing serum  detecting M-9 antigen, black circles  represent 
titers  1:500 to 1:104, stippled circles 1:10 to 1:250, and open circles, no reaction.  (<1:10). 
24  other  monoclonal  antibodies  detecting  a  series  of differentiation  antigens  on 
renal  cancer,  lung cancer,  and  ovarian  cancer  and  ABH  blood  group  antigens  were 
included in these tests. No reactions with newborn or adult melanocytes were observed. 
Influence of In  Vitro Culture Conditions on Antigen Expression.  Melanocytes require TPA 
and  cholera  toxin  for  at  least  the  first  4  d  of  culture  to  stimulate  melanocyte 
proliferation  and  to  inhibit  overgrowth  of keratinocytes  and  fibroblasts.  However, 
after this brief exposure, cultures can be maintained without growth factors for several 
weeks before melanocytes die or become overgrown by fibroblasts.  To investigate the 
influence of growth  factors on antigen expression,  melanocytes were grown  for 4  d  in 
TPA  and  cholera toxin conditioned  media  and  then  for 3  wk in  (a)  culture  medium 
without  growth  factors,  (b)  culture  medium  with either TPA  or cholera  toxin,  or  (c) 
culture medium  with both TPA  and cholera toxin. We did not observe any difference 
in antigen expression when melanocytes were cultured under these various conditions; HOUGHTON, EISINGER, ALBINO, CAIRNCROSS,  AND OLD  1761 
monoclonal antibodies detecting antigens M-1  through M-6, M-9, M-10, and M-34 
were used in these tests. Studies were also carried out to determine whether melanoma 
cell lines grown in the presence of TPA and cholera toxin would change their surface 
antigenic phenotype. Of the  28  antigenic systems tested  on 8  melanoma cell lines, 
only M-34 antigen was  influenced by the presence of growth  factors;  SK-MEL-19, 
which characteristically expresses little or no M-34 antigen, converted to M-34  + after 
growth in TPA and cholera toxin. 
To  reduce  the  possibility  that  length  of  time  in  culture  might  alter  antigen 
expression, most tests were carried out with melanocyte cultures between passage  1 
and 3.  However, little difference in antigen expression was seen when melanocytes 
were tested later at passage 8,  12, or 19. M-4 and M-5 antigens, which are markers of 
newborn and fetal melanocytes, appear to be exceptions because they could not be 
\ 
detected on newborn melanocytes after five passages in culture. 
Subsets of Melanoma Cell Lines Defined by Melanocyte Differentiation Antigens.  25 mela- 
noma cell  lines were  typed  for  the  expression of M-2,  M-3,  HLA-DR,  M-4,  M-6, 
M-9  and  M-10  antigens. These seven antigens were  selected  because they defined 
subsets of melanomas (present on some melanomas but not others)  and had distinct 
patterns of expression on fetal/newborn and adult melanocytes. Three antigens, HLA- 
DR, M-2, and M-3, can be assumed to be early markers of melanocyte differentiation 
because they are expressed on melanomas but not on melanocytes. Antigens M-4 and 
M-6  appear  on  fetal  and  newborn  melanocytes but  not  adult  melanocytes  and, 
therefore, signal an intermediate phase in melanocyte differentiation. M-9 and M-10 
appear  to  be  late  markers  in  the  melanocyte  lineage  because  they  are  strongly 
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FIG. 4.  Serological  typing of 25 melanoma cell lines for melanocyte differentiation markers. Black 
rectangles represent antigen expression  by melanoma cell lines, as determined by titers of 1:500 to 
1  : 107 for mouse monoclonal antibodies and 1  : 10 to 1  : 105 for human serum detecting M-9 antigen. 
Morphology: E,  epithelioid; S,  spindle-shaped; D,  polydendritic. Pigmentation  was  estimated 
visually by the intensity of brown or black pigment in the cell pellet. Tyrosinase activity was 
expressed as a ratio of tritiated HeO produced by melanoma cuhure/tritiated H20 produced by 
nonpigmented renal cancer culture (standard). F
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Flo.  6.  Proposed  pathway  of melanocyte  differentiation based on surface antigenic phenotype  and 
morphology. The phenotype of melanomas corresponding to early, intermediate, or late stages in 
the proposed melanocyte pathway is also illustrated. In this scheme, M-2, M-3, and  HLA-DR 
antigens are early melanocyte  markers, M-4, M-5, and M-6 antigens are intermediate markers, and 
M-9, and  M-10 antigens are late melanocyte markers. M-18 antigen is found at  all stages of 
melanocyte differentiation and is present on all melanoma cells. 
expressed on adult melanocytes as compared with fetal and newborn melanocytes. 
The surface phenotypes of the  25 melanoma lines  appear to correspond to early, 
intermediate,  or late  phases of melanocyte differentiations.  5  melanomas expressed 
only early markers, 10 intermediate markers, and 10 late melanocyte markers (Fig. 4). 
Evidence for the  significance of these  differences  comes from  a  comparison of the 
pattern of surface antigens with other differentiation characteristics, such as pigmen- 
tation, morphology, and  tyrosinase  (Fig.  4).  The majority of melanomas expressing 
early  antigenic  markers  are  epithelioid  (Fig.  5a),  and  these  melanoma  lines  lack 
pigmentation  and  tyrosinase activity.  Fig.  5b  shows the  morphology of a  cell  line 
belonging to the intermediate group, and the resemblance to the bipolar morphology 
of melanocytes from fetal and newborn skin is apparent.  Melanomas expressing late 
melanocyte markers  frequently  have  a  polydendritic  morphology similar  to  adult 
melanocytes, with heavy pigmentation and high levels of tyrosinase activity (Fig.  5 c). 
Melanocyte Differentiation Pathway.  From these studies of differentiation antigens on 
melanocytes and melanomas, a surface antigenic map of the melanocyte lineage can 
be proposed (Fig.  6).  At least  three distinct stages in melanocyte differentiation can 
be defined - precursor, intermediate, and mature. We infer the features of melanocyte 
precursors from the characteristics of melanomas expressing early markers of differ- 
entiation.  The  intermediate  and  mature  phases  of  melanocyte  development  are 
defined by markers that distinguish  fetal/newborn melanocytes from adult melano- 
cytes.  On  the  basis  of surface  antigens,  morphology, pigmentation,  and  tyrosinase 1764  SURFACE ANTIGENS OF  MELANOCYTES AND MELANOMAS 
activity, three classes of melanomas can be identified, corresponding to the features of 
normal  melanocytes  at  the  early,  intermediate,  or  mature  phases  in  melanocyte 
differentiation. 
Discussion 
The  process of cellular  differentiation  is  accompanied  by changes  in  the  surface 
antigenic phenotype, and surface antigens that distinguish cells belonging to distinct 
differentiation lineages or distinguish cells at different phases in the same differentia- 
tion  lineage  are  referred  to  as  differentiation  antigens  (14).  Initial  recognition  of 
differentiation  antigens  came  about  through  analysis  of surface  antigens  of T  cell 
leukemias of the mouse and the description of the TL (15), Thy-1  (16), and Lyt (17) 
series of antigens.  The  analysis  of these  T  cell  differentiation  antigens  was  greatly 
simplified  by the  availability  of normal  T  cells  from  the  thymus  and  from  other 
lymphoid organs for a  side-by-side comparison with leukemic T  cells. Although  the 
study of differentiation antigens on T  cells and B cells of mouse and man is relatively 
advanced,  little  is  known  about  differentiation  antigens  displayed  on  normal  and 
neoplastic  cells  belonging  to  other  lineages,  and  this  is  due  to  the  difficulty  of 
obtaining a ready source of the appropriate normal cell type. The recently described 
technique to culture melanocytes from normal skin (6) provides a renewable source of 
proliferating  cells  for  the  analysis  of melanocyte  differentiation  antigens,  and  the 
monoclonal antibodies detecting cell surface antigens of melanoma provide the initial 
serological probes for this analysis. 
On the basis of reactions with melanocytes from fetal, newborn, or adult skin, we 
identified antigens that appear to be early, intermediate, or late markers ofmelanocyte 
differentiation.  The  late  markers,  such  as  M-10,  are  strongly  expressed  by  adult 
melanocytes. Intermediate melanocyte markers, such as M-4, are found on fetal and 
newborn melanocytes but not adult melanocytes. With regard to antigens detected on 
melanomas but  not  on fetal, newborn, or adult  melanocytes, we propose that  these 
are early markers expressed by melanocyte precursors but not by ceils further down 
the melanocyte pathway. Although  a  melanocyte precursor cell has not as yet been 
identified in the skin, we suggest that its surface phenotype would correspond to the 
M-2 +,  M-3 +,  HLA-DR  +  subset  of melanomas.  One  candidate  for  the  melanocyte 
precursor is the indeterminate cell type found in the basal layer of the epidermis (18). 
Because these cells express HLA-DR but do not contain  melanosomes or tyrosinase 
activity,  they  have  been  considered  precursors  of  Langerhans  cells  in  the  upper 
epidermis, but it is equally plausible that some indeterminate cells are precursors of 
melanocytes. Two other explanations for the expression of antigens on melanoma cells 
but  not melanocytes should be considered.  One possibility is that a  second differen- 
tiation pathway for pigment cells exists. A bifurcation could occur in the neural crest 
pathway, with one arm leading to epidermal melanocytes and another arm leading 
to nevus cells. HLA-DR, M-2, and M-3 would be expressed only on nevus cells and 
pigmented tumors derived from them, hut not on normal or malignant melanocytes. 
The other possibility, which we consider less likely, is that these antigens are unrelated 
to neural crest differentiation but are the result of abnormal gene expression induced 
during the process of malignant transformation and tumor progression. 
In  addition  to  the  value  that  these  melanocyte  differentiation  markers have  for 
investigating  normal  melanocytes  and  their  precursors,  it  seems  likely  that  such 
markers will also provide new ways to analyze and classify melanomas. For instance, 
melanoma cell lines fall into one of three general classes on the basis of expression of HOUGHTON,  EISINGER, ALBINO, CAIRNCROSS, AND OLD  1765 
early,  intermediate,  or late  melanocyte antigens.  Although  the  significance of this 
classification awaits the results of comparable studies with noneuhured  tissue speci- 
mens, there is an evident correlation between the surface antigenic phenotype of the 
cultured melanoma line and other differentiation characteristics, such as morphology, 
pigmentation,  and  tyrosinase  activity.  Melanomas  expressing  early  markers  but 
lacking intermediate or late markers have an epithelioid  morphology, lack pigmen- 
tation,  and  have  low  levels  of tyrosinase.  In  contrast,  melanomas  expressing  late 
markers, such as M-9 and M-10, have a spindle-shaped or polydendritic morphology, 
are pigmented, and have high levels of tyrosinase. Intermediate classes of melanoma 
can be distinguished that express intermediate melanocyte markers, and these gener- 
ally have a spindle morphology, little pigmentation, and low levels of tyrosinase. 
A  question  that  cannot  be  answered  with  the  available  evidence  is  whether 
melanomas arise at any one of a number of stages throughout the melanocyte lineage 
or whether  there  is  a  preferential  stage  for malignant  transformation.  The  finding 
that  the  phenotypes of melanoma correspond  to  distinct  phases  in  the  melanocyte 
pathway  could  be  explained  by  transformation  of early,  intermediate,  or  mature 
progenitors, or alternatively, by transformation of early progenitors with transform- 
ants having the ability to undergo variable but characteristic degrees of differentiation 
to later stages of melanocyte differentiation.  The overlapping phenotypic character- 
istics  of  melanoma  cell  lines  from  different  individuals  is  consistent  with  either 
explanation.  However,  the  striking  phenotypic  variation  of  different  melanoma 
metastases derived from a single patient (19), where individual metastases were found 
to  show  characteristics  of either  early  or  intermediate  melanocyte stages,  is  more 
consistent with a model of early stage transformation and variable capacity of progeny 
cells to differentiate toward later stages. This matter may be clarified by the results of 
current  attempts  to  transform  melanocytes  from  different  stages  of differentiation 
with chemical or physical carcinogens. 
Summary 
The  surface  antigens  of melanocytes  from  newborn  and  adult  skin  have  been 
analyzed  with  monoclonal  antibodies  detecting  cell  surface  antigens  of malignant 
melanoma. Antigenic markers that distinguish early, intermediate, and mature stages 
in  melanocyte differentiation  have been  defined.  The characteristics of the  normal 
melanocyte precursor have been inferred from the features of melanomas that express 
early markers of melanocyte differentiation.  A  rudimentary surface antigen  map of 
cells  undergoing  melanocyte differentiation  and  a  new  classification of melanomas 
based on the expression of melanocyte differentiation antigens are proposed. 
We wish to acknowledge the expert technical assistance  of Ms. Susan Messing  and Ms. Olga 
Marko. 
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